Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9UI10: Variant p.Arg374Cys

Translation initiation factor eIF2B subunit delta
Gene: EIF2B4
Feedback?
Variant information Variant position: help 374 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Cysteine (C) at position 374 (R374C, p.Arg374Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In VWM4. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 374 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 523 The length of the canonical sequence.
Location on the sequence: help RRFRVVVVDSRPWLEGRHTL R SLVHAGVPASYLLIPAASYV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         RRFRVVVVDSRPWLEGRHTLRSLVHAGVPASYLLIPAASYV

Mouse                         RRFRVVVVDSRPRLEGRHMLHSLVRAGVPTSYLLIPAASYV

Rat                           RRFRVVVVDSRPRLEGRHMLHCLVRAGVPTSYLLIPAASYV

Bovine                        RQFRVVVVDSRPRLEAKHTLRSLVRAGVPASYLLIPAASYV

Rabbit                        RKFRVVVVDSRPRLEGRHMLRFLVRAGVPASYLLIPAASYV

Slime mold                    KKFRLIIVDSRPKHEGRELLHRLVLHGVKITYIMLHAVSYI

Baker's yeast                 KNIKVIVVDSRPLFEGRKMAETLRNAGVNVMYALITSLDTI

Fission yeast                 KKFRVVVVDSRPEFEGRVCLKLLTEHGIECTYVMISALSYI

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 523 Translation initiation factor eIF2B subunit delta
Helix 369 – 378



Literature citations
Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter.
van der Knaap M.S.; Leegwater P.A.J.; Koenst A.A.M.; Visser A.; Naidu S.; Oudejans C.B.M.; Schutgens R.B.H.; Pronk J.C.;
Ann. Neurol. 51:264-270(2002)
Cited for: VARIANTS VWM4 VAL-228; GLN-357 AND CYS-374; VARIANT GLY-306; Identification of ten novel mutations in patients with eIF2B-related disorders.
Ohlenbusch A.; Henneke M.; Brockmann K.; Goerg M.; Hanefeld F.; Kohlschutter A.; Gartner J.;
Hum. Mutat. 25:411-411(2005)
Cited for: VARIANTS VWM4 GLN-209; ARG-269 AND CYS-374;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.